Study reveals artery stiffness from common cancer drug

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient at least 18 years old, * Patient with colorectal cancer of the adenocarcinoma type, stage IV, histologically confirmed, mutated or wild tumor RAS status (exons 2, 3 and 4 of the KRAS and NRAS genes), mutated or wild BRAF status, naive in antineoplastic treatment * Patient eligible to start systemic carcinological treatment including bevacizumab in combination with chemotherapy based on IV fluoropyrimidine, * General condition WHO grade less than or equal to 3, * Life expectancy greater than 4 months, * Patient who has read and understood the information letter and signed the consent form, * Patient affiliated to a social security scheme, * Effective contraception (see WHO definition) in women of childbearing age (negative pregnancy test). For postmenopausal women, a confirmatory diagnosis should be obtained (amenorrhea not medically induced for at least 12 months before the inclusion visit). Exclusion Criteria: * Previous exposure to anti-VEGF, * Exposure to treatment for metastatic disease in the 12 months prior to inclusion, * Other histologically proven neoplasia not considered in complete remission or considered in complete remission for less than two years, * Bilateral carotid breath, * Absence of peripheral pulse of the two upper limbs, * Contraindication to AVASTIN 25 mg / ml concentrate for solution for infusion: * Hypersensitivity to the active substance or to any of the excipients, * Hypersensitivity to Chinese hamster ovarian cell products or other human or humanized recombinant antibodies, * Patients: * having undergone a major surgical intervention in the 28 days preceding the inclusion or as long as the surgical wound is not completely healed, * Unhealed ulcer or wound, * having uncontrolled pre-existing hypertension (PAS\> or = 170 mm Hg after three repeated measurements at rest), * having a history of arterial thromboembolism (transient ischemic attack (TIA), cardiovascular accident (stroke) or recent (\<6 months) and / or symptomatic myocardial infarction (MI) * having had an invasive dental procedure in the 28 days preceding inclusion, * with known proteinuria\> 2g / 24h or in whom proteinuria\> 2g / 24h is discovered in the case of a positive urine strip 3+ for proteins (excluding urinary tract infection), * on aspirin\> 325 mg / d, * with a colonic prosthesis in place, * Systemic treatment with anti-EGFR monoclonal antibodies, * Presence or history of lymphedema of the bilateral upper limbs, * Patient with poor understanding of spoken or written French, * Patient deprived of liberty by an administrative or judicial decision or patient placed under the protection of justice, under guardianship or curatorship, * Pregnant or lactating woman or wishing to breastfeed within 6 months after the last administration of the treatment, * Patient participating in another drug trial / having participated in another drug trial within 30 days of inclusion, * History of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for his participation